Loss of function germline mutations in RAD51D in women with ovarian carcinoma

被引:35
|
作者
Wickramanyake, Anneka
Bernier, Greta [2 ,3 ]
Pennil, Christopher
Casadei, Silvia [2 ]
Agnew, Kathy J.
Stray, Sunday M. [2 ]
Mandell, Jessica [2 ]
Garcia, Rochelle L. [4 ]
Walsh, Tom [2 ]
King, Mary-Claire [2 ]
Swisher, Elizabeth M. [1 ,2 ]
机构
[1] Univ Washington, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol,Sch Med, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA
关键词
RAD51D; Ovarian cancer; Breast cancer; CANCER; BREAST;
D O I
10.1016/j.ygyno.2012.09.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. RAD51D, a gene in the Fanconi Anemia-BRCA homologous recombination pathway, has recently been shown to harbor germline mutations responsible for ovarian carcinoma in multiply affected families. We aimed to extend these results to ovarian carcinoma in the general population. Methods. We sequenced RAD51D in germline DNA from 360 individuals with primary ovarian, peritoneal or fallopian tube carcinoma who were not selected for age of cancer onset or family history. We also sequenced RAD51D in 459 probands from 226 high risk breast cancer families who were wild type for 21 breast and ovarian cancer genes. Results. Of 360 cases, three (0.8%) carried loss-of-function mutations in RAD51D. All three subjects had ovarian carcinoma; one was also diagnosed with a synchronous endometrial carcinoma. Only one of the three subjects had a family history of breast or ovarian cancer. Combined with previous data for this series, 23.9% of women with unselected ovarian, fallopian tube, or peritoneal carcinoma carried a germline loss-of-function mutation in any of 13 tumor suppressor genes. Among the 449 women and 10 men with familial breast cancer, none carried a loss of function mutation in RAD51D. Conclusions. These data support the previous observation that loss-of-function mutations in RAD51D predispose to ovarian carcinoma but not to breast carcinoma. We conclude that inherited ovarian cancer is highly heterogeneous genetically, and that approximately one in four ovarian carcinoma patients carry a germline mutation in a known tumor suppressor gene that confers high risk. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:552 / 555
页数:4
相关论文
共 50 条
  • [31] Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
    Vysotskaia, Valentina
    Kaseniit, K. Eerik
    Bucheit, Leslie
    Ready, Kaylene
    Price, Kristin
    Taber, Katherine Johansen
    CANCER, 2020, 126 (03) : 549 - 558
  • [32] Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
    Nesic, Ksenija
    Kondrashova, Olga
    Hurley, Rachel M.
    McGehee, Cordelia D.
    Vandenberg, Cassandra J.
    Ho, Gwo-Yaw
    Lieschke, Elizabeth
    Dall, Genevieve
    Bound, Nirashaa
    Shield-Artin, Kristy
    Radke, Marc
    Musafer, Ashan
    Chai, Zi Qing
    Ghamsari, Mohammad Reza Eftekhariyan
    Harrell, Maria, I
    Kee, Damien
    Olesen, Inger
    McNally, Orla
    Traficante, Nadia
    DeFazio, Anna
    Bowtell, David D. L.
    Swisher, Elizabeth M.
    Weroha, S. John
    Nones, Katia
    Waddell, Nicola
    Kaufmann, Scott H.
    Dobrovic, Alexander
    Wakefield, Matthew J.
    Scott, Clare L.
    CANCER RESEARCH, 2021, 81 (18) : 4709 - 4722
  • [33] RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC
    Xu, Jing
    Dai, Yilin
    Gao, Yi
    Chai, Ranran
    Lu, Chong
    Yu, Bing
    Kang, Yu
    Xu, Congjian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [34] Inherited Mutations in Women With Ovarian Carcinoma
    Norquist, Barbara M.
    Harrell, Maria I.
    Brady, Mark F.
    Walsh, Tom
    Lee, Ming K.
    Gulsuner, Suleyman
    Bernards, Sarah S.
    Casadei, Silvia
    Yi, Qian
    Burger, Robert A.
    Chan, John K.
    Davidson, Susan A.
    Mannel, Robert S.
    DiSilvestro, Paul A.
    Lankes, Heather A.
    Ramirez, Nilsa C.
    King, Mary Claire
    Swisher, Elizabeth M.
    Birrer, Michael J.
    JAMA ONCOLOGY, 2016, 2 (04) : 482 - 490
  • [35] Serous Tubal Intraepithelial Carcinoma in a Risk-reducing Salpingo-oophorectomy Specimen From a RAD51D Mutation Carrier: A Case Report
    Gregory-Davis, Kalin J.
    Walker, Allison
    Colello, Laura S.
    McKinnon, Wendy
    Everett, Elise
    Chang, Martin C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2023, 42 (01) : 89 - 92
  • [36] About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants
    Gutierrez-Enriquez, Sara
    Bonache, Sandra
    Ruiz de Garibay, Gorka
    Osorio, Ana
    Santamarina, Marta
    Ramon y Cajal, Teresa
    Esteban-Cardenosa, Eva
    Tenes, Anna
    Yanowsky, Kira
    Barroso, Alicia
    Montalban, Gemma
    Blanco, Ana
    Cornet, Monica
    Gadea, Neus
    Infante, Mar
    Caldes, Trinidad
    Diaz-Rubio, Eduardo
    Balmana, Judith
    Lasa, Adriana
    Vega, Ana
    Benitez, Javier
    de la Hoya, Miguel
    Diez, Orland
    INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (09) : 2088 - 2097
  • [37] The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer
    Ciyu Yang
    Angela G. Arnold
    Amanda Catchings
    Vikas Rai
    Zsofia K. Stadler
    Liying Zhang
    Breast Cancer Research and Treatment, 2021, 185 : 869 - 877
  • [38] The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer
    Yang, Ciyu
    Arnold, Angela G.
    Catchings, Amanda
    Rai, Vikas
    Stadler, Zsofia K.
    Zhang, Liying
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 869 - 877
  • [39] A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
    Ngu, Siew-Fei
    Ngan, Hextan Y. S.
    Chan, Karen K. L.
    CANCER DRUG RESISTANCE, 2022, 5 (03) : 662 - 666
  • [40] Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
    Imterat, Majdi
    Harter, Philipp
    Rhiem, Kerstin
    Heitz, Florian
    Schneider, Stephanie
    Concin, Nicole
    Moubarak, Malak
    Welz, Julia
    Vrentas, Vasileios
    Traut, Alexander
    Hahnen, Eric
    Schmutzler, Rita
    du Bois, Andreas
    Ataseven, Beyhan
    CANCERS, 2023, 15 (09)